

International Handbook of Occupational Therapy Interventions

Chapter 35

Upper-Limb Movement Training in Children Following Injection of Botulinum Neurotoxin A

Brian Hoare and Remo N. Russo

After injection and intensive therapy, the client was really happy to be able to catch and throw a ball with his school friends.

Abstract Botulinum Neurotoxin A (BoNT-A) is a useful medication for the reduction of spasticity and dystonia in the upper limb of children with cerebral palsy (CP). The method of toxin delivery, dose, and muscle selection criteria are established. Children who are being treated require appropriate assessment at the impairment and activity levels of functioning. Once injected, children require specific therapy delivered by an occupational therapist (OT) according to the specified goals of the intervention set out, prior to injection, by the child, family, and health care workers. Botulinum neurotoxin injection offers the child with cerebral palsy a window of opportunity in which to develop further skills in upper limb functioning. Further research using rigorous scientific design evaluating specific therapy regimes and other interventions is required to enable more specific protocols to be established.

Keywords Botulinum Neurotoxin • Child • Cerebral palsy • Upper limb

Definition and Background

Cerebral palsy is a static lesion of the immature brain (Taft, 1995) leading to disorders of tone, posture, and movement (Bax et al., 2005). Affected children can experience varying degrees of positive (e.g., increased tone) and negative (e.g., sensory impairment) features of the disorder, and each can have impact on functioning (Graham, 2000). The predominant disorders of tone in cerebral palsy are *spasticity* (Graham, 2000) and *dystonia* (Autti-Ramo et al., 2001). The topography of involvement can affect the upper limb in children with all forms of cerebral palsy, and impact on function.

Both spasticity and dystonia can be influenced by botulinum Neurotoxin A (BoNT-A) injection (Brin, 1997).

BoNT-A is a protein product of *Clostridium botulinum*, an anaerobic bacterium (Jankovic and Brin, 1997). Its action is to block the release of acetylcholine from the motor nerve terminal to the muscle cell, causing a chemical denervation (Brin, 1997). The pharmacologic effect of BoNT-A lasts up to 12 weeks (Graham, 2000); however, functional benefits lasting much longer can be experienced (Lowe et al., 2006; Russo et al., 2007).

BoNT-A is injected directly into the affected muscles, which are targeted according to clinical evaluation and desired functional goals (Russman et al., 1997). In the upper limb these muscles usually include the elbow flexors, wrist flexors, pronators, thumb adductor and opponens, and finger flexors (Lowe et al., 2006; Russman et al., 1997). Dosing regimes and dilution volumes for BoNT-A are established (Russman et al., 1997). The child usually has some form of analgesia for the procedure (Lowe et al., 2006; Russman et al., 1997; Russo et al., 2007), and the muscles to be injected are usually identified by surface anatomy, palpation, and some form of localization (such as with a stimulator, electromyography, or ultrasound) to ensure correct needle placement (O'Brien, 1997).

Purpose

BoNT-A injected directly into the affected muscle results in relaxation of the muscle, providing a window of opportunity to allow for therapy intervention. The overall aim of the occupational therapy intervention in children with cerebral palsy is to improve occupational performance, and whatever changes are achieved in capacity are best achieved in the context of improving skills (Kielhofner, 1995).

Method

Candidates for the Intervention

For children with cerebral palsy with *more severe upper limb impairment* (i.e., Manual Ability Classification System [MACS] level IV to V) (Eliasson et al., 2006), BoNT-A is injected to reduce muscle spasticity and muscle tone, increase range of motion, improve agonist-antagonist balance, delay the need for or complement orthopedic procedures, improve tolerance to splinting, maintain hygiene and skin integrity, improve cosmesis, manage pain, and prevent long-term deformity.

For children with *less severe upper limb impairment* (i.e., MACS level I to III) (Eliasson et al., 2006), hand skill development, improved occupational performance, and functional goal attainment are often the goals for treatment.

Epidemiology

Cerebral palsy occurs with an incidence of approximately 2 to 2.5 per 1000 live births (Reddihough and Collins, 2003). Upon careful and thorough clinical assessment, it is estimated that up to 50% of the population of children with cerebral palsy will benefit from upper limb injection of Botulinum Neurotoxin A.

The Role of the Occupational Therapist in Applying the Intervention

The role of the occupational therapist (OT) is integral in the identification of appropriate children for Botulinum Neurotoxin A injection, the selection of muscles for injection, pre- and postinjection assessment, goal setting, and the provision of adjunct interventions following injection.

Results

Clinical Application

Assessment of the Upper Limb Before Injection of BoNT-A

Assessment of impairment level should occur in larger muscle groups in the upper limb in children who receive BoNT-A injection. These measures assist in (1) identifying muscles with significant spasticity interfering with function, (2) selecting the muscle for injection, (3) determining the dosage, and (4) choosing the direction of the postinjection therapy.

Clinical range of motion is measured together with spasticity using the modified Tardieu scale (Boyd and Graham, 1999; Mackey, et al., 2004). This measure of spasticity is obtained when a joint is moved as fast as possible through its range of movement (V3 velocity) and the angle of “catch” elicited is measured using a goniometer. The difference between the angle of “catch” (R1) and the full passive range of movement (R2) reflects the potential range available in the joint if spasticity is eliminated.

Assessment of activity level requires careful observation of how spasticity and dystonia impact on the child’s task performance. Videotaped assessments such as the Melbourne Assessment of Unilateral Upper Limb Function (Randall et al., 2001) and the Assisting Hand Assessment (Krumlinde-Sundholm et al., 2007) provide valuable information on a child’s typical movement abilities. These observations are critical for (1) guiding muscle selection, (2) directing postinjection therapy, and (3) providing objective data measuring the change postinjection.

Goal Setting

The Canadian Occupational Performance Measure (COPM) (Law et al., 1994) is designed to detect change in a person's occupational performance. The COPM is an extremely useful tool for identifying and prioritizing goals pre- and postinjection of BoNT-A. The COPM responses can be transferred and scaled using the Goal Attainment Scaling (Kiresuk et al., 1994). This complementary approach enables goal identification, articulation, and measurement (Lowe et al., 2006; Wallen et al., 2007).

Intervention Postinjection of BoNT-A

Impairment Level: Stretching and Splinting

Active or passive manipulation of a muscle for 20 minutes immediately postinjection increases the efficacy of BoNT-A in the injected muscle and reduces diffusion to distant muscles (Minamoto et al., 2007). It is therefore important to provide immediate stretch to the child postinjection by applying a splint or encouraging active movement.

The general recommendation for *splint use* is for a minimum of 6 hours per night. This is based on evidence that contractures did not occur in children with cerebral palsy when lower limb muscles were stretched for more than 6 hours (Tardieu et al., 1988). However, evidence that static splinting maintains the mechanical-elastic properties of muscle is weak (Pin et al., 2006), with support for this intervention coming from animal studies (Williams, 1988; Williams et al., 1988) and limited evidence in the adult lower limb literature (Light et al., 1984; Steffen and Mollinger, 1995). The optimal splint design or position is currently unknown. However, day splinting using neoprene and Lycra garments is not recommended, with limited evidence for their efficacy (Corn et al., 2003; Knox, 2003; Nicholson et al., 2001) and the potential to reduce antagonist muscle movement.

Casting is clinically indicated when fixed contractures are present. This achieves a low-load prolonged duration muscle stretch. Typically, a serial program is implemented whereby a cast is reapplied every 3 to 7 days, gradually increasing the passive range of movement across a joint until the desired range is achieved. Three to four serial casts will usually be adequate to achieve the desired range of movement, and static splinting following the casting program is recommended. However, due to a lack of evidence for the efficacy of casting in this setting (Lannin et al., 2007), decisions and casting protocols are based on clinical experience.

Activity Level: Occupational Therapy

It is generally recommended that occupational therapy should commence 2 to 4 weeks following injection, with research supporting intensive bursts of movement-based training provided once or twice weekly for 2 to 3 months following injection.

However, the optimal program of occupational therapy has not been established, and the following discussion concerns the emerging trends in therapy after injection of BoNT-A.

Traditional upper limb occupational therapy practice involves a bimanual approach to training that is underpinned by several theoretical models (Chapparo and Ranka, 1997; Kielhofner, 1995; Law et al., 1997). Occupational therapists target the treatment of hand skills with specific task practice using a motor skill acquisition frame of reference (Kaplan and Bedell, 1999). This approach is well supported by recent advances in knowledge in the areas of neuroscience, basic mechanisms of hand function, and, more specifically, motor control and motor learning theories (Eliasson, 2005).

The practical application of a movement-based paediatric occupational therapy program, targeting activity level outcomes, should include the *following principles* based on a motor skill acquisition frame of reference (Kaplan and Bedell, 1999):

- Task analysis to identify if performance is limited by execution of movement or motor planning difficulties (i.e., sequencing of movements) (Steenbergen and Gordon, 2006; Steenbergen et al., 2007).
- Repetitive whole task practice of challenging, motivating, and purposeful activities (i.e., toys and games), carefully selected to facilitate development of goal-based skills and independence with task completion.
- Use modeling, physical assistance, verbal cues, or environmental adaptation to enable the child to understand the critical features of the task and the environment.
- Facilitate the children's learning and understanding of the role of their assisting hand (i.e., hemiplegic assisting hand) using active problem solving.
- Grading of physical or verbal assistance provided to complete tasks.
- Provide feedback focusing on the movement outcome, task, and environment rather than on the specific movement performance.
- Provide opportunities for the child to practice tasks in a range of contexts and environments.

Charles and Gordon (2006) have recently presented a similar protocol described as *Hand-Arm Bimanual Intensive Training (HABIT)*, in which intensive practice of bimanual tasks is undertaken over a 2-week period. In this protocol, however, the therapist does not handle the child to facilitate movement or assist in task completion, but environmental adaptation is used. Specific movements required for task completion are also practiced repetitively and intensively using a protocol similar to behavioral shaping (Morris and Taub, 2001).

Constraint-induced movement therapy (CIMT) (Taub, et al., 1999) (see Chapters 30 and 31) combined with botulinum Neurotoxin A injection can be effective in providing intensive practice to young children with hemiplegia who do not spontaneously use their affected upper limb or have a significant developmental disregard. As the emerging evidence is as supportive of modified CIT as it is of CIT (Hoare et al., 2007), a modified protocol using a mitt and 2 hours of daily practice for 2 months is suggested. A bimanual training program should follow shortly after.

Goal-directed programs for children over the age of 5 years are aimed at maximizing the learning and performance of skills required for school and daily life that

need to be considered. Goal-directed training is an activity-based approach to therapy aiming to improve a person's ability to engage in meaningful activities (Mastos et al., 2007). Programs are implemented using principles of motor learning (Schmidt and Lee, 1999) and are based on four components: (1) selection of a meaningful goal, (2) analysis of baseline performance, (3) intervention/practice regime, and (4) evaluation of outcome (Mastos et al., 2007).

Prior to injection of botulinum Neurotoxin A, the Canadian Occupational Performance Measure (Law et al., 1994) and Goal Attainment Scaling (Kiresuk et al., 1994) can be used to identify a meaningful goal for a child. The therapist must observe the child's baseline performance of the task to identify the specific areas of limitation. This process facilitates treatment planning and may also assist in determining appropriate muscles to be targeted for injection with BoNT-A. Following injection, the occupational therapy intervention focuses on specific and repetitive practice of the chosen task. The role of the therapist is to create a learning situation to develop active problem solving, exploration of alternative strategies, and repetitive practice.

Evidence-Based Practice

There is a growing body of high-quality research supporting the efficacy of upper limb occupational therapy intervention in children with cerebral palsy. More recent trials (Boyd, 2004; Greaves, 2004; Lowe et al., 2006; Russo et al., 2007; Wallen et al., 2007) evaluating the effects of BoNT-A and occupational therapy with occupational therapy alone have demonstrated positive gains on activity level outcomes in both the treatment and control groups.

Goal-directed training has been shown to be effective in attainment of meaningful goals and improved self-care and mobility as measured by the Pediatric Evaluation of Disability Inventory (Ahl et al., 2005; Ketelaar et al., 2001).

Discussion

BoNT-A is used to reduce spasticity and dystonia in affected muscles. This offers a window of opportunity to effect impairment and activity-based treatment strategies that can assist the child in upper limb functioning. Although specific regimes of upper limb therapy require further rigorous scientific evaluation, therapy postinjection targeting functional tasks identified by goal setting is gaining evidence of efficacy.

References

- Ahl, L. E., Johansson, E., Granat, T., & Carlberg, E. B. (2005). Functional therapy for children with cerebral palsy: an ecological approach. *Dev Med Child Neurol*, 47(9), 613–619
- Autti-Ramo, I., Larsen, A., Taimo, A., & von Wendt, L. (2001). Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. *European Journal of Neurology*, 8 Suppl 5, 136–144

- Bax, M., Goldstein, M., Rosenbaum, P., Leviton, A., Paneth, N., Dan, B., et al. (2005). Proposed definition and classification of cerebral palsy, April 2005. *Dev Med Child Neurol*, 47(8), 571–576
- Boyd, R. (2004). The central and peripheral effects of botulinum toxin A in children with cerebral palsy PhD dissertation, La Trobe University, Melbourne
- Boyd, R. N., & Graham, H. K. (1999). Objective measurement of clinical finding in the use of botulinum toxin type A for the management of children with cerebral palsy. *Eur J Neurol*, 6(Suppl. 4), S23–S35
- Brin, M. F. (1997). Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. *Muscle Nerve Suppl*, 6, S146–168
- Chapparo, C., & Ranka, J. (1997). Occupational Performance Model (Australia) (Vol. Monograph 1). Sydney: OP Network - Total Print Control
- Charles, J., & Gordon, A. M. (2006). Development of hand-arm bimanual intensive training (HABIT) for improving bimanual coordination in children with hemiplegic cerebral palsy. *Dev Med Child Neurol*, 48(11), 931–936
- Corn, K., Imms, C., Timewell, G., Carter, C., Collins, L., Dubbeld, S., et al. (2003). Impact of second skin Lycra splinting on quality of upper limb movement in children. *British Journal of Occupational Therapy*, 66, 464–472
- Eliasson, A. C. (2005). Improving the use of hands in daily activities: aspects of the treatment of children with cerebral palsy. *Phys Occup Ther Pediatr* 25(3), 37–60
- Eliasson, A. C., Krumlinde-Sundholm, L., Rosblad, B., Beckung, E., Arner, M., Ohrvall, A. M., et al. (2006). The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. *Dev Med Child Neurol* 48(7), 549–554
- Graham, H. K. (2000). Botulinum toxin A in cerebral palsy: functional outcomes.[comment]. *Journal of Pediatrics*, 137(3), 300–303
- Greaves, S. (2004). The effect of botulinum toxin A injections on occupational therapy intervention outcomes for children with spastic hemiplegia., La Trobe University, Melbourne
- Hoare, B. J., Wasiak, J., Imms, C., & Carey, L. (2007). Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy. *Cochrane Database Syst Rev*(2), CD004149
- Jankovic, J., & Brin, M. F. (1997). Botulinum toxin: historical perspective and potential new indications. *Muscle Nerve Suppl* 6, S129–145
- Kaplan, M. T., & Bedell, G. (1999). Motor skill acquisition frame of reference. In P. Kramer & J. Hinojosa (Eds.), *Frames of Reference for Pediatric Occupational Therapy*, (2nd ed., pp. 401–429). Baltimore: Williams and Wilkins
- Ketelaar, M., Vermeer, A., Hart, H., van Petegem-van Beek, E., & Helders, P. J. (2001). Effects of a functional therapy program on motor abilities of children with cerebral palsy. *Phys Ther*, 81(9), 1534–1545
- Kielhofner, G. (1995). *A Model of Human Occupation. Theory and Application* (2nd ed.). Baltimore: Williams and Wilkins
- Kiresuk, T. J., Smith, J. E., & Cardillo, J. E. (1994). *Goal Attainment Scaling: Applications, Theory and Measurement*, Hillsdale, NJ: Lawrence Erlbaum
- Knox, V. (2003). The use of Lycra garments in children with cerebral palsy: A report of a descriptive clinical trial. *British Journal of Occupational Therapy*, 66, 71–77
- Krumlinde-Sundholm, L., Holmefur, M., Kottorp, A., & Eliasson, A. C. (2007). The Assisting Hand Assessment: current evidence of validity, reliability, and responsiveness to change. *Dev Med Child Neurol*, 49(4), 259–264
- Lannin, N. A., Novak, I., & Cusick, A. (2007). A systematic review of upper extremity casting for children and adults with central nervous system motor disorders. *Clin Rehabil*, 21(11), 963–976
- Law, M., Baptiste, S., Carswell, A., McColl, M. A., Polatajko, H., & Pollock, N. (1994). *The Canadian Occupational Performance Measure*. (2nd ed.). Toronto: Canadian Association of Occupational Therapists
- Law, M., Stanton, S., Polatajko, H., Baptiste, S., Thompson-Franson, T., Kramer, C., et al. (1997). *Enabling Occupation. An occupational therapy perspective*. Ottawa: CAOT Publications

- Light, K. E., Nuzik, S., Personius, W., & Barstrom, A. (1984). Low-load prolonged stretch vs. high-load brief stretch in treating knee contractures. *Phys Ther*, 64(3), 330–333
- Lowe, K., Novak, I., & Cusick, A. (2006). Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. *Dev Med Child Neurol*, 48(3), 170–175
- Mackey, A. H., Walt, S. E., Lobb, G., & Stott, N. S. (2004). Intraobserver reliability of the modified Tardieu scale in the upper limb of children with hemiplegia. *Dev Med Child Neurol*, 46(4), 267–272
- Mastos, M., Miller, K., Eliasson, A. C., & Imms, C. (2007). Goal-directed training: linking theories of treatment to clinical practice for improved functional activities in daily life. *Clin Rehabil*, 21(1), 47–55
- Minamoto, V. B., Hulst, J. B., Lim, M., Peace, W. J., Bremner, S. N., Ward, S. R., , et al. (2007). Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation. *Dev Med Child Neurol*, 49(12), 907–914
- Morris, D. M., & Taub, E. (2001). Constraint-induced therapy approach to restoring function after neurological injury. *Top Stroke Rehabil*, 8(3), 16–30
- Nicholson, J. H., Morton, R. E., Attfield, S., & Rennie, D. (2001). Assessment of upper-limb function and movement in children with cerebral palsy wearing Lycra garments. *Developmental Medicine & Child Neurology*, 43(6), 384–391
- O'Brien, C. F. (1997). Injection techniques for botulinum toxin using electromyography and electrical stimulation. *Muscle Nerve Suppl*, 6, S176–180
- Pin, T., Dyke, P., & Chan, M. (2006). The effectiveness of passive stretching in children with cerebral palsy. *Dev Med Child Neurol*, 48(10), 855–862
- Randall, M., Carlin, J. B., Chondros, P., & Reddihough, D. (2001). Reliability of the Melbourne assessment of unilateral upper limb function. *Developmental Medicine & Child Neurology*, 43(11), 761–767
- Reddihough, D. S., & Collins, K. J. (2003). The epidemiology and causes of cerebral palsy. *Australian Journal of Physiotherapy*, 49(1), 7–12
- Russman, B. S., Tilton, A., & Gormley, M. E., Jr. (1997). Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. *Muscle Nerve Suppl*, 6, S181–193
- Russo, R. N., Crotty, M., Miller, M. D., Murchland, S., Flett, P., & Haan, E. (2007). Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. *Pediatrics*, 119(5), e1149–1158
- Schmidt, R. A., & Lee, T. D. (1999). *Motor control and learning: a behavioural emphasis*, 2nd ed.. Champaign, IL: Human Kinetics Publishers
- Steenbergen, B., & Gordon, A. M. (2006). Activity limitation in hemiplegic cerebral palsy: evidence for disorders in motor planning. *Dev Med Child Neurol*, 48(9), 780–783
- Steenbergen, B., Verrel, J., & Gordon, A.M. (2007). Motor planning in congenital hemiplegia. *Disabil Rehabil*, 29(1), 13–23
- Steffen, T. M., & Mollinger, L. A. (1995). Low-load, prolonged stretch in the treatment of knee flexion contractures in nursing home residents. *Phys Ther*, 75(10), 886–895; discussion 895–887
- Taft, L. T. (1995). Cerebral Palsy. *Pediatrics in Review*, 16(11), 411–418; quiz 418
- Tardieu, C., Lespargot, A., Tabary, C., & Bret, M. D. (1988). For how long must the soleus muscle be stretched each day to prevent contracture? *Dev Med Child Neurol*, 30(1), 3–10
- Taub, E., Uswatte, G., & Pidikiti, R. (1999). Constraint-Induced Movement Therapy: a new family of techniques with broad application to physical rehabilitation—a clinical review. *J Rehabil Res Dev*, 36(3), 237–251
- Wallen, M., O'Flaherty, S. J., & Waugh, M. C. (2007). Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. *Arch Phys Med Rehabil*, 88(1), 1–10

- Williams, P. E. (1988). Effect of intermittent stretch on immobilised muscle. *British Medical Journal*, *47*, 1014–1016
- Williams, P. E., Catanese, T., Lucey, E.G., & Goldspink, G. (1988). The importance of stretch and contractile activity in the prevention of connective tissue accumulation in muscle. *J Anat*, *158*, 109–114